---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-024134"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:27:57.846423+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences reports positive interim Phase 1a results for ABI-1179 in recurrent genital herpes

## Summary
- ABI-1179 had a half-life of ~4 days and high exposure across 50mg-300mg doses, supporting once-weekly oral dosing.
- ABI-1179 was well-tolerated with no serious adverse events and all treatment-emergent AEs mild and unrelated.
- Company plans to move directly into Phase 1b, running concurrently with Phase 1b of ABI-5366.
- Interim Phase 1b data for both ABI-1179 and ABI-5366 anticipated in fall 2025.
- ABI-1179 contributed by Gilead Sciences under the Assembly Bio-Gilead collaboration.

## SEC filing metadata
- accession: 0000950170-25-024134
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017025024134/0000950170-25-024134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017025024134/asmb-20250220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-024134
- JSON: https://secwatch.observer/filing/0000950170-25-024134.json
- Plain text: https://secwatch.observer/filing/0000950170-25-024134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.